Related Experiment Video
Updated: Jun 13, 2025

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
Published on: August 12, 2016
Individualized selection of recent glucose monitoring devices for self-management based on competitive features
Olga Krylova1, Sevara Marchenko2, Alexandra Ermolaeva3
1Olga Krylova Associate Professor, Department of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Objective:
Goal of the study was to systematically review competitive advantages of medical devices for glucose monitoring in diabetic patients.
Method:
The review is done systematically according to SALSA criteria and PRISMA guidelines. The search for eligible articles was held from February 16th 2023 to March 1st 2023 in Russian and English languages. The results were synthesized narratively, tabularly, and visually. The search was conducted in the following databases of scientific literature: PubMed, IEEE Xplore, Google Scholar, CyberLeninka, and eLibrary.
Results:
Twenty-two out of fifty-two manuscripts met the inclusion criteria. The most promising and advantageous characteristics of the evaluated devices, as identified by researchers, include the following: the capability for noninvasive examination; features that facilitate use by patients with fine motor, hearing, and visual impairments; add-ons and software designed to improve patient compliance, including in pediatric populations; and device attributes that enhance the speed and accuracy of analysis while being free of iatrogenic effects.
Conclusions:
With increasing prevalence of diabetes, glycemic control is crucial for preventing complications. The market offers numerous glucose monitoring devices (GMDs) with varying features, making selection challenging. Our study systematically categorized the strengths of each GMD model for diabetic patients, aiding informed device selection.
Related Concept Videos
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Glinides
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Type 2 and Gestational
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

